Insights

Gathering insights about Procaps…

Similar companies to Procaps

Procaps Tech Stack

Procaps uses 8 technology products and services including cdnjs, jQuery CDN, Font Awesome, and more. Explore Procaps's tech stack below.

cdnjs
Content Delivery Network
jQuery CDN
Content Delivery Network
Font Awesome
Font Scripts
SWFObject
Miscellaneous
Bulma
UI Frameworks
GoDaddy
Web Hosting
prettyPhoto
Web Tools And Plugins
Twitter
Widgets

Media & News

ProCook Group (LON:PROC) Trading Up 5.9% – Should You Buy?
ProCook Group plc (LON: PROC - Get Free Report)'s share price was up 5.9% on Wednesday. The company traded as high as GBX 36 and last traded at GBX 36. Approximately 58 shares changed hands during trading, a decline of 100% from the average daily volume of 43,764 shares. The stock had previously closed at
Nov 06, 2025 | www.defenseworld.net
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that the first patient has been dosed in Part 2 of the Phase 2 DENALI clinical trial (NCT05128825) of azenosertib in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). As previously disclosed, the Company aligned with the U.S. Food and Drug Administration (FDA) on the design of DENALI Part 2, which allows for seamless enrollment in the two parts of the trial: Part 2a is designed to confirm the primary dose-of-interest with a target enrollment of approximately 30 patients at each of two dose levels: 400mg QD 5:2 and 300mg QD 5:2 (intermittent daily dosing on a five days on, two days off dosing schedule).
Apr 28, 2025 | www.globenewswire.com
Procaps Group Secures $130 Million in Equity Investment and Completes Comprehensive Debt Restructuring, as New Investors Take Over Strategic Leadership
New Investors Take Over the Strategic Leadership as Headquarters Move to Bogotá, Marking the Start of a New Chapter of Growth, Execution, and Transformation under Enhanced Governance
Apr 09, 2025 | www.globenewswire.com
Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release
Corcept Therapeutics Incorporated's relacorilant met the primary endpoint in the phase 3 ROSELLA study for platinum-resistant ovarian cancer patients, boosting shares by over 90% the very same day. Upcoming catalysts include full trial data release at a medical conference, NDA filing in Q3 2025, and MAA submission to the EMA shortly afterward. Relacorilant also targets hypercortisolism with endogenous Cushing's Syndrome patients with an FDA PDUFA date set for December 30, 2025, based on positive GRACE, GRADIENT, and phase 2 study data.
Apr 01, 2025 | seekingalpha.com
Procaps Group Receives Delisting Notice From Nasdaq
MIAMI and BARRANQUILLA, Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that the Company received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) that it has determined to delist the Company's ordinary shares on Nasdaq. The delisting is a result of the Company's failure to demonstrate compliance with Nasdaq Listing Rules 5250(c)(1) and 5250(c)(2) for failing to file periodic and interim financial reports. As a result of the forgoing, the Company's ordinary shares are expected to commence trading on the Expert Market operated by the OTC Markets Group, Inc. (“OTC”), commencing on February 4, 2025.
Feb 03, 2025 | www.globenewswire.com
Procaps Group Receives Additional Delinquency Letter
MIAMI and BARRANQUILLA, Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that, as anticipated, on December 31, 2024, the Company received notice from The Nasdaq Stock Market LLC (“Nasdaq”) of an additional filing delinquency relating to the Company's interim financial statements for the period ended June 30, 2024.
Jan 03, 2025 | www.globenewswire.com
Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates
MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team.
Dec 20, 2024 | www.globenewswire.com

Procaps's Email Address Formats

Procaps uses at least 2 format(s):

Procaps Email Formats	Example	Percentage
FLast@procaps.com.co	JDoe@procaps.com.co	98%
FiLast@procaps.com.co	JoDoe@procaps.com.co	1%
Last@procaps.com.co	Doe@procaps.com.co	1%

Frequently Asked Questions

What is Procaps's stock symbol?

Procaps is a publicly traded company; the company's stock symbol is PROC.

What is Procaps's official website and social media links?

Procaps's official website is procapslaboratorios.com and has social profiles on LinkedIn.

How much revenue does Procaps generate?

As of December 2025, Procaps's annual revenue is estimated to be $5B.

What is Procaps's SIC code NAICS code?

Procaps's SIC code is 2834 - Pharmaceutical Preparations NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Procaps have currently?

As of December 2025, Procaps has approximately 3K employees across 4 continents, including South AmericaNorth AmericaEurope. Key team members include Chief Commercial Officer (cco): L. A. P. A.Chief Of Planning And Business Development Of Procaps Bolivia: S. Q. H.Head Of Procurement: M. L. B. C.. Explore Procaps's employee directory with LeadIQ.

What industry does Procaps belong to?

Procaps operates in the Pharmaceutical Manufacturing industry.

What technology does Procaps use?

Procaps's tech stack includes cdnjsjQuery CDNFont AwesomeSWFObjectBulmaGoDaddyprettyPhotoTwitter.

What is Procaps's email format?

Procaps's email format typically follows the pattern of FLast@procaps.com.co. Find more Procaps email formats with LeadIQ.

When was Procaps founded?

Procaps was founded in 1977.

Procaps

Q: What is Procaps's official website and social media links?

Procaps's official website is procapslaboratorios.com. Procaps has social profiles on LinkedIn.

Q: How many employees does Procaps have currently?

Procaps has approximately 3K employees.

Q: What technology does Procaps use?

Procaps's tech stack includes Google Maps, Hotjar, Power BI, Swiper, Open Graph.

Pharmaceutical ManufacturingAtlántico, Colombia1001-5000 Employees

Somos una empresa que transforma vidas llevando salud y bienestar accesible a los pacientes y a las comunidades que servimos

Company Overview

Website: procapslaboratorios.com
SIC Code: 2834 - Pharmaceutical Preparations
Stock Symbol: PROC
NAICS Code: 3254 - Pharmaceutical and Medicine Manufacturing
Founded: 1977
Employees: 1001-5000

Media & News

Funding & Financials

$250M$500M
Procaps's revenue is estimated to be in the range of $250M$500M

Funding & Financials

$250M$500M
Procaps's revenue is estimated to be in the range of $250M$500M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Procaps

Almac Group

Qualicaps

Patheon Inc.

STIPLASTICS

Vetter Pharma

Lonza

CapsCanada

Capsugel

Harro Höfliger Verpackungsmaschinen GmbH

Procaps Tech Stack

Media & News

ProCook Group (LON:PROC) Trading Up 5.9% – Should You Buy?

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

Procaps Group Secures $130 Million in Equity Investment and Completes Comprehensive Debt Restructuring, as New Investors Take Over Strategic Leadership

Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release

Procaps Group Receives Delisting Notice From Nasdaq

Procaps Group Receives Additional Delinquency Letter

Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates

Procaps's Email Address Formats

Frequently Asked Questions

What is Procaps's stock symbol?

What is Procaps's official website and social media links?

How much revenue does Procaps generate?

What is Procaps's SIC code NAICS code?

How many employees does Procaps have currently?

What industry does Procaps belong to?

What technology does Procaps use?

What is Procaps's email format?

When was Procaps founded?

Procaps

Company Overview

Media & News

ProCook Group (LON:PROC) Trading Up 5.9% – Should You Buy?

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

Procaps Group Secures $130 Million in Equity Investment and Completes Comprehensive Debt Restructuring, as New Investors Take Over Strategic Leadership

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?